Parkwalk is a growth EIS fund manager that backs disruptive technologies emerging from the UK's leading universities and research institutions.
Portfolio
27
companies
AUM
£360M
under management
AccelerComm
AccelerComm delivers high-performance 5G technology for satellite networks.
Arkivum
Arkivum provides long-term data safeguarding and data usability solutions.
Brainomix
Artificial intelligence software for medical imaging diagnostics.
Cambridge GaN Devices
Developer of power semiconductor devices using Gallium-Nitride on Silicon technology.
Cambridge Touch Technologies
Cambridge Touch Technologies provides advanced touch solutions for smart devices.
Ceryx Medical
Ceryx Medical develops next-generation bioelectronic therapies for heart failure.
Congenica
Congenica provides software that accelerates genomic data analysis for personalised medicine.
Cytora
Cytora develops artificial intelligence software for commercial insurance underwriting.
DefiniGEN
DefiniGEN creates human cell models to support drug discovery and preclinical research.
Diffblue
Diffblue provides autonomous generative artificial intelligence software that automates unit test generation for developers.
Echopoint Medical
Echopoint Medical develops optical sensing microcatheters for heart disease diagnosis.
Enhanced Genomics
Biotechnology company pioneering 3D multi-omics to identify drug targets for common diseases.
Entia
Entia develops remote patient monitoring and blood testing technology for cancer treatment.
GeoSpock
GeoSpock develops high performance database technology for large scale spatial and temporal data analytics.
HexagonFab
HexagonFab builds analytical lab instruments to streamline biopharmaceutical discovery and production.
Ikarovec
Developer of novel gene therapies for major ophthalmic indications.
MoA Technology
MoA Technology develops next-generation herbicides to combat global weed resistance.
Mogrify
Mogrify develops in vivo reprogramming therapies to transform patient outcomes in degenerative diseases.
Orthox
Orthox develops natural implants to repair damaged knee cartilage.
Paragraf
Paragraf manufactures scalable graphene-based electronic devices.
Pathfinder Medical
Medical device company improving outcomes for vascular procedures.
PredictImmune
PredictImmune develops prognostic tools for guiding treatment in immune-mediated diseases.
Psyomics
Psyomics develops artificial intelligence software to improve mental health assessment and diagnosis.
Qkine
Qkine manufactures specialist bioactive proteins for stem cell and regenerative medicine applications.
Semarion
Semarion develops microcarrier technology that turns adherent cells into assay-ready reagents.
Symetrica
Symetrica manufactures advanced radiation detection and threat identification devices for security and military sectors.
xWatts
xWatts provides automated energy management and optimisation for complex estates.
Neil Cameron
Investment Director
Neil serves as Investment Director at Parkwalk and holds non-executive directorships across multiple portfolio companies.
LinkedIn
Alastair Kilgour
Chief Investment Officer
Alastair is the founder of Parkwalk Advisors and brings board-level experience across life sciences and innovation companies, including PhoreMost and Queen Mary Innovation.
LinkedInCassie Doherty
Investor
Cassie brings life sciences investment experience from roles at IP Group, Parkwalk Advisors, and Northern Gritstone. She also serves as a member of the board of trustees at Leeds Hospitals Charity.
LinkedIn
Alun Williams
Investment Director
Alun is an investment director at Parkwalk Advisors and co-founded the firm. He brings board and investor director experience from multiple companies.
LinkedIn
Martin Glen
Investment Director
Martin serves as an investment director at Parkwalk Advisors and holds directorships across several portfolio companies. He brings extensive board-level experience from firms including Gripable, Psyomics, and Wayland Additive.
LinkedInJohn Pearson
Chief Investment Officer
Anne Dobrée
Investment Director at Parkwalk
Anne serves as investment director at Parkwalk Advisors and holds non-executive directorships at several companies, including Enhanced Genomics and Pathfinder Medical.
LinkedInThe Series C round was co-led by Oxford Science Enterprises and Supernova Invest to support product development.
"When we helped spin Moa out from the University of Oxford’s Plant Sciences Department in 2017, we saw that its technology platform had a unique and important approach to address the market’s need for herbicides capable of breaking weed resistance,"
Parkwalk led the round to help the University of Cambridge spinout expand its manufacturing and commercial reach.
The extension brings total Series C financing to £18.8m with participation from US investor Modi Ventures.
"This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care. Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments."
The London-based energy management platform raised the capital from Cambridge Enterprise Ventures, Cambridge Angels, Parkwalk, and R42 to scale its product development.
"Our mission is straightforward but ambitious: to decarbonise the world’s most complex real estate in a way that is intelligent, automated and scalable. We don’t just tell you what to do, we do it for you. This funding allows us to double down on the growth and product investment needed to compete at scale."
The financing round was backed by BGF, Parkwalk, and Meltwind to drive therapeutics discovery in autoimmune and other common diseases.
"Our founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets. We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies."
